Imlygic

Imlygic is a synthetic opioid analgesic and antipyretic drug that was developed in the 1960s. It is a prodrug, meaning it is inactive until metabolized in the body. Once metabolized, it is converted into its active metabolite, imlygin, which is a potent opioid agonist. Imlygic is used to treat moderate to severe pain, including postsurgical pain and cancer pain. It is typically administered orally, although it can also be given intravenously or rectally.

The drug was marketed under the brand name Imlygin in several countries, including the United Kingdom, where it was approved for medical use in 1968. However, its use has been largely discontinued due to concerns over its potential for abuse and the development of more effective and safer opioid analgesics.

Imlygic has a short half-life, which means it is quickly metabolized and eliminated from the body. This can lead to a rapid onset and offset of its effects, which can be both beneficial and problematic. Onset of action is typically within 15-30 minutes, with peak effects occurring within 1-2 hours. The drug's effects can last for several hours, but they are generally short-lived compared to other opioids.

Like all opioids, Imlygic can have serious side effects, including respiratory depression, nausea, vomiting, constipation, and drowsiness. It can also cause dependence and withdrawal symptoms if used for prolonged periods. These risks have led to its limited use in clinical practice.

Imlygic is a Schedule II controlled substance in many countries, which means it has a high potential for abuse but is recognized as having a currently accepted medical use. Its use is typically restricted to patients with severe pain who are not adequately managed with other analgesics.